Summary:
1. Glaukos Corporation director, Marc Stapley, sold 15,000 shares for $1.9 million.
2. Stapley’s transaction history, the structural context behind the sale, and the implications for his ownership were discussed.
3. Glaukos received FDA approval for a supplement to help glaucoma patients, impacting the company’s stock performance.
Rewritten Article:
Glaukos Corporation, a leading ophthalmic device maker specializing in glaucoma solutions, recently made headlines when one of its directors, Marc Stapley, executed a direct sale of 15,000 shares for a transaction value of approximately $1.9 million on January 22, 2026. This notable insider sale came after a challenging year for the company’s stock, which had experienced a decrease of around 25% in 2025. However, things seemed to be turning around as the stock saw a 4.3% increase in January 2026, thanks in part to Glaukos’ recent FDA approval for the re-administration of a supplement to help glaucoma patients manage their condition.
The transaction summary revealed that Stapley’s sale of 15,000 shares was significant compared to his previous dispositions, with post-transaction direct holdings falling to 37,449 shares valued at approximately $4.71 million. The structural context behind the sale was attributed to the exercise of 15,000 stock options, which were immediately sold, as disclosed in the filing’s derivative context. This transaction represented 0.07% of outstanding shares, with no options outstanding for Stapley’s future capacity.
Glaukos Corporation, with a market capitalization of $6.85 billion, offers ophthalmic medical devices and pharmaceutical therapies tailored for glaucoma and related eye conditions. The company caters to ophthalmologists and healthcare institutions in the US and internationally, focusing on patients with mild-to-moderate open-angle glaucoma and related conditions. Despite operating at a zero profit level for over five years, Glaukos remains a dominant force in the pharmaceutical market, meeting strong demand for products related to eye health.
In conclusion, while the recent insider sale by Marc Stapley may have raised some eyebrows, Glaukos Corporation’s future looks promising with the FDA approval of its supplement and the potential for share prices to improve in the short term. Investors should keep an eye on the company’s performance as it navigates through the challenges of the industry and strives to maintain its position as a key player in the ophthalmic solutions market.
